Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.
[fabry disease]
Data
on
prevalence
,
natural
history
,
and
effect
of
enzyme
replacement
therapy
(
ERT
)
on
hearing
loss
(
HL
)
in
Fabry
disease
(
FD
)
are
scarce
.
This
is
a
retrospective
study
with
cross-sectional
and
longitudinal
analyses
.
Low
and
high
-frequency
HL
in
the
Dutch
FD
cohort
was
studied
in
four
groups
:
classical
and
non-classical
FD
patients
with
or
without
ERT
.
To
study
effects
of
ERT
,
longitudinal
data
,
corrected
for
age
and
gender
according
to
ISO-
1999
guidelines
,
were
analyzed
with
mixed
models
.
In
the
cross-sectional
analysis
,
107
FD
patients
(
41
males
)
,
median
age
47
.
6
Â
years
(
18
.
8
-
80
.
6
)
were
analyzed
.
At
baseline
,
i
.
e
.
,
before
start
of
ERT
,
HL
was
present
in
18
patients
(
16
.
8
Â
%
)
,
of
whom
four
had
bilateral
sensorineural
HL
.
HL
was
more
often
present
in
patients
with
the
classical
phenotype
than
non-classical
patients
(
p
 
<
 
0
.
01
)
.
Likewise
,
males
had
more
often
HL
than
females
.
Compared
to
the
general
population
,
FD
patients
show
a
median
HL
of
8
.
2
Â
dB
at
low
frequencies
(
p
 
<
 
0
.
01
)
and
29
.
5
Â
dB
at
ultra-
high
frequencies
(
p
 
<
 
0
.
01
)
.
Longitudinal
analyses
(
n
 
=
 
91
)
revealed
that
ERT
treated
patients
show
a
similar
rate
of
decline
,
not
significantly
different
from
healthy
controls
.
Adult
FD
patients
,
especially
classical
affected
males
,
show
impaired
hearing
.
Longitudinal
analyses
during
ERT
in
these
patients
demonstrates
a
decline
of
HL
similar
to
healthy
controls
,
but
HL
present
before
initiation
of
therapy
can
not
be
reversed
.
Whether
early
therapy
can
prevent
hearing
loss
is
unknown
.
Diseases
Validation
Diseases presenting
"impaired hearing"
symptom
fabry disease
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom